Boston Scientific completes $615M acquisition of Apollo Endosurgery, expanding its portfolio of minimally invasive medical technologies.
- Apollo Endosurgery is now part of Boston Scientific (NYSE:BSX) as the latter’s acquisition of the former is now complete.
- The $615M deal ($10 per share) was announced at the end of November 2022.
- Boston Scientific (BSX) said that the acquisition’s impact on EPS is expected to be immaterial in 2023, but accretive after this year.
Source: SeekingAlpha